Wedbush analyst David Nierengarten downgraded Intellia Therapeutics to Neutral from Outperform with a price target of $16, down from $21 after the company presented updated data from their newly nominated preclinical program in AML and a first look at the company's development program in hereditary angioedema at the Keystone Symposia's Engineering the Genome Conference this week. In a research note to investors, Nierengarten says that while he appreciates HAE as an opportunity for Intellia, the company has also discontinued alpha-1 antitrypsin deficiency and primary hyperoxaluria Type 1.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here